Diagnosis of lung cancer depends on lung histology or sputum shedding cytology. Screening methods for lung cancer mainly include X-ray chest X-ray and sputum cytology, low-dose spiral CT, blood and sputum biomarkers, and exhalation gas monitoring.
As people's awareness of cancer increases and technology advances, as well as private and government support, these are some of the factors that are expected to drive market growth.

Market Analysis and Insights: Global Lung Cancer Diagnostics Market
The global Lung Cancer Diagnostics market size is projected to reach US$ 2783 million by 2027, from US$ 1883.5 million in 2020, at a CAGR of 5.7% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Lung Cancer Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Lung Cancer Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Lung Cancer Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Lung Cancer Diagnostics market.

Global Lung Cancer Diagnostics Scope and Market Size
Lung Cancer Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Lung Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Immunoassays
Flow Cytometry
Rapid Tests
Molecular Assays
Tissue Arrays
Circulating Tumor Cells
Pharmacodiagnostics
Biomarkers
Other

Segment by Application
Industrial
Healthcare
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Roche Diagnostics
BioMérieux
Qiagen
Advpharma
AIT Austrian Institute of Technology
Courtagen Life Sciences
DiagnoCure
BioMark Diagnostics
Mayo Clinic
HalioDx SAS